Stanford University researchers have identified a naturally occurring molecule, dubbed BRP, that sharply suppresses appetite and drives fat loss in animal studies, according to findings released this week. The compound was surfaced through an artificial intelligence screening process designed to uncover appetite-regulating pathways beyond those targeted by existing obesity drugs. In laboratory animals, BRP reduced food intake by as much as 50 percent, the researchers reported, while promoting fat loss without the significant muscle loss associated with some current treatments.
The molecule appears to act on a distinct brain pathway rather than the GLP-1 receptor targeted by Ozempic and similar medications, a difference researchers say may avoid the digestive side effects that lead some patients to discontinue treatment. If the results hold in human trials, BRP could offer a more precise approach to obesity management, though the team cautioned that animal findings frequently fail to translate into clinical success. No timeline for human testing was announced, and independent experts not involved in the work stressed that safety and efficacy in people remain unproven.
Independent reporting synthesized from primary wires and global correspondents.